OrthoPediatrics (KIDS) Q2 2026 earnings review
Record Revenue and Inflecting Profitability Overshadow Scoliosis Hiccup
OrthoPediatrics reached a major inflection point in 26Q2, crossing the $70M revenue threshold for the first time ($70.5M, +15% YoY). More importantly, the company is proving it can scale profitably. Operating expenses grew just 3%, driving a record Adjusted EBITDA of $6.8M and reducing cash burn by 78% YoY to just $3.1M. While the Scoliosis segment suddenly contracted 9% due to capital sales timing, a massive 26% surge in Trauma & Deformity more than compensated. Management subsequently raised FY26 revenue guidance to $265-$269M while holding firm on achieving free cash flow breakeven.
🐂 Bull Case
The long-promised transition to self-sustaining growth is materializing. Generating 15% top-line growth while holding OpEx growth to 3% proves the core business is highly scalable. FCF breakeven is now a near certainty.
Trauma & Deformity accelerated to 26% YoY growth. With the 3P Platform and other new products rolling out, the segment is aggressively taking market share from legacy competitors exiting the pediatric space.
🐻 Bear Case
The 9% contraction in Scoliosis reveals deep vulnerability to the timing of 7D capital sales and international stocking orders. This lumpiness will continue to frustrate quarterly modeling.
Management has previously noted that set availability, not surgeon demand, is the primary rate limiter for new product growth. Capping set deployments at $10M to protect cash flow could artificially constrain revenue.
⚖️ Verdict: 🟢
Bullish. The 9% drop in Scoliosis is a noisy headline, but the underlying fundamentals are excellent. Achieving 26% growth in the largest segment (T&D) while dramatically shrinking cash burn validates management's 'super cycle' narrative.
Key Themes
Trauma & Deformity (T&D) Breakout
T&D was the engine of Q2, printing $52.6M and Accelerating to 26% YoY growth (up from 14% in Q1 and 17% in late 2025). This was driven by Cannulated Screws, PNP Femur, PediPlates, Pega systems, and the addition of 3P Hip. This validates the 'innovation super cycle' thesis and confirms the company is capturing share as large competitors abandon pediatric orthopedics.
Scoliosis Reverses on Capital Sale Timing
Scoliosis revenue Reversing to a 9% YoY decline ($16.9M) is the quarter's primary blemish. Management blamed decreased 7D Technology capital revenue and lower international set sales. While underlying implant usage (Response fusion, Verteglide) remains strong, the lumpiness of capital placements continues to inject unneeded volatility into the top line.
Operating Leverage is Now a Reality
For years, KIDS was a high-cash-burn story. Q2 proves the model is flipping. Total operating expenses grew only 3% YoY to $56.4M, compared to 15% revenue growth. This discipline translated directly to the bottom line, with Adjusted EBITDA hitting a record $6.8M and FCF burn dropping 78% to just $3.1M. This Accelerating profitability is the most crucial narrative shift for the stock.
OPSB (Specialty Bracing) Continues to Scale
The OrthoPediatrics Specialty Bracing (OPSB) strategy remains highly accretive. By acquiring clinics (acquihires) and opening greenfield locations, the company is locking in capital-efficient growth. The integration is driving increased same-store sales and boosting the T&D segment, proving the shift toward full-disease-state treatment is working.
New Partnerships Expanding Portfolio
KIDS signed an exclusive distribution agreement with OSSIO to bring a bio-integrative, metal-free fixation technology to pediatric hospitals. This supplements the organic pipeline and provides another high-value bundle component to leverage its dominant pediatric commercial channel.
Set Deployment Balancing Act
Management's commitment to FCF breakeven in 2026 relies on capping instrument set deployments at ~$10M annually. However, in prior quarters, management admitted that set availability for new products like VerteGlide was the primary 'rate limiter' for growth. By starving capital expenditures to achieve FCF targets, they may be capping their own near-term growth ceiling.
Other KPIs
Accelerating from 72% in Q2 2025. This 200 basis point expansion was driven by higher sales volumes and favorable product mix, shaking off the margin drag from international stocking orders seen in prior quarters.
A massive 78% YoY improvement from the $13.9 million burned in Q2 2025. This was driven by higher Adjusted EBITDA, lower set deployments, and tighter working capital management, keeping the company firmly on track for full-year FCF breakeven.
Accelerating 22% YoY, primarily driven by strong procedure volumes rather than lumpy stocking set sales. Recent EU MDR approvals are successfully unlocking broader product availability in Europe.
Guidance
Accelerating. Raised from the prior range of $263.0M-$267.0M. The new midpoint ($267.0M) implies 12% to 14% growth over FY25. Beating Q2 by ~$2M allowed management to simply flow the beat through to the full year, indicating typical management conservatism rather than a material change in H2 expectations.
Stable. Management reiterated this target, which represents a massive leap from FY25's $14.8M. Given the $6.8M printed in Q2 alone, this annual target appears highly achievable barring a sudden collapse in gross margins.
Stable. The company reiterated its commitment to generating zero cash burn for the full year. With Q2 usage down to $3.1M and seasonality typically favoring H2, the company is perfectly positioned to self-fund its operations moving forward.
Key Questions
Scoliosis Trajectory and 7D Backlog
Scoliosis revenue declined 9% due to 7D capital sales and international set timing. What is the current backlog for 7D placements, and is there a risk that capital equipment budgets at children's hospitals are structurally tightening?
Set Deployment vs Demand
You reiterate your goal of ~$10M in set deployments for FY26 to achieve FCF breakeven. Given the 26% growth in T&D, are you currently leaving revenue on the table because you lack the instrument sets to support incoming surgeon demand?
OSSIO Partnership Impact
Can you frame the financial impact of the new OSSIO distribution agreement? How quickly can this bio-integrative technology be rolled out to your existing clinic network, and does it carry a margin profile accretive to your 74% corporate average?